CD276 and leukemia: Importantly, in vivo imaging showed that both 2.5 × 106 and 5 × 106 doses of BiCisCAR T cells completely eradicated leukemia expressing GPC2 or CD276 and prevented the recurrence of leukemia (Figure 9, B and C, and Supplemental Figure 11, B and C).